Stockscreener 앱 받기
6.28
3.97%
0.24
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
BNP Paribas Financial Markets Increases Stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
When (LXEO) Moves Investors should Listen - Stock Traders Daily
Charles Schwab Investment Management Inc. Buys 33,013 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics appoints new CFO amid growth - Investing.com
Lexeo Therapeutics Appoints Dr. Kyle Rasbach as CFO - TipRanks
Lexeo Therapeutics Names Kyle Rasbach Chief Financial Officer - MarketWatch
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer - The Manila Times
Lexeo Therapeutics, Inc. Appoints Kyle Rasbach as Chief Financial Officer - Marketscreener.com
Lexeo Therapeutics' SWOT analysis: gene therapy stock's potential and pitfalls - Investing.com
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for catalysts By Investing.com - Investing.com Nigeria
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for catalysts - Investing.com India
Frazier Life Sciences Management L.P. Invests $11.31 Million in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Point72 Asset Management L.P. Makes New $3.35 Million Investment in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Janus Henderson Group PLC Purchases 599,203 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
RA Capital Management L.P. Reduces Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
LXEOLexeo Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Verition Fund Management LLC Boosts Stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Eventide Asset Management LLC Has $16.78 Million Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Sold by Braidwell LP - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Insider Spends US$105k Buying More Shares In Lexeo Therapeutics - Simply Wall St
Paula H. Cholmondeley Bought 96% More Shares In Lexeo Therapeutics - Yahoo Finance
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Analysts - MarketBeat
Insider Buying: Paula Cholmondeley Acquires 15,000 Shares of Lex - GuruFocus.com
Can Lexeo's HEROIC-PKP2 Data Reignite Stock Rally? - RTTNews
Lexeo stock hits 52-week low at $5.8 amid market challenges - Investing.com India
Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation - Yahoo Finance
(LXEO) Trading Advice - Stock Traders Daily
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
FY2024 EPS Forecast for Lexeo Therapeutics Cut by Analyst - MarketBeat
FY2024 Earnings Estimate for LXEO Issued By Leerink Partnrs - MarketBeat
HC Wainwright Has Negative Estimate for LXEO FY2024 Earnings - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
Lexeo Therapeutics Advances Cardiac Portfolio Amid Financial Report - TipRanks
Janus Henderson Group PLC's Strategic Acquisition in Lexeo Thera - GuruFocus.com
Eventide Asset Management's Strategic Reduction in Lexeo Therape - GuruFocus.com
Lexeo Therapeutics, Inc. Appoints Tolga Tanguler to Its Board of Directors - Marketscreener.com
Lexeo Therapeutics Strengthens Leadership with New Board Appointment - TipRanks
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results - The Manila Times
Lexeo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lexeo Therapeutics Secures FDA Alignment, Reports $157M Cash Position Despite Q3 Loss | LXEO Stock News - StockTitan
Lexeo stock hits 52-week low at $7.54 amid market challenges By Investing.com - Investing.com South Africa
Lexeo stock hits 52-week low at $7.54 amid market challenges - Investing.com India
Lexeo Therapeutics' Gene Therapy LX1001 Increases APOE2 Expression in Patients With Alzheimer Disease - CGTLive™
Analysts Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) PT at $22.14 - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Earns Buy Rating from HC Wainwright - MarketBeat
Lexeo shares dip on early data with Alzheimer's gene therapy - pharmaphorum
Lexeo reports positive Alzheimer's drug trial results - Investing.com India
Lexeo reports positive Alzheimer's drug trial results By Investing.com - Investing.com South Africa
Lexeo Therapeutics Announces Positive Interim Data for - GlobeNewswire
How now, tau? ‘Newer science’ shines in Lexeo Alzheimer’s data - BioWorld Online
2.88%
2.65%
자본화:
|
볼륨(24시간):